ULTRAGENYX PHARMACEUTICAL
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
ULTRAGENYX PHARMACEUTICAL
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2010-01-01
Address:
Novato, California, United States
Country:
United States
Website Url:
http://www.ultragenyx.com
Total Employee:
501+
Status:
Active
Contact:
+1 415 483 8800
Email Addresses:
[email protected]
Total Funding:
1.14 B USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Content Delivery Network Amazon Font Awesome
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals is a biotechnology company with a focus on the development of innovative treatments for rare inherited diseases.
Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA specializes in the development of women's health care products.
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals develops and markets a global array of treatments for dermatological conditions and advanced tissue care.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.
Santhera Pharmaceuticals
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.
Surrozen
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Versiti
Versiti provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
AlloVir
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-07-18 | GeneTx Biotherapeutics | GeneTx Biotherapeutics acquired by Ultragenyx Pharmaceutical | 75 M USD |
| 2017-09-18 | Dimension Therapeutics | Dimension Therapeutics acquired by Ultragenyx Pharmaceutical | 152.3 M USD |
Investors List
Takeda Ventures
Takeda Ventures investment in Post-IPO Equity - Ultragenyx Pharmaceutical
Takeda
Takeda investment in Post-IPO Equity - Ultragenyx Pharmaceutical
F-Prime Capital
F-Prime Capital investment in Series B - Ultragenyx Pharmaceutical
Adage Capital Management
Adage Capital Management investment in Series B - Ultragenyx Pharmaceutical
HealthCap
HealthCap investment in Series B - Ultragenyx Pharmaceutical
Pappas Ventures
Pappas Ventures investment in Series B - Ultragenyx Pharmaceutical
TPG Growth
TPG Growth investment in Series B - Ultragenyx Pharmaceutical
BlackRock Private Equity Partners
BlackRock Private Equity Partners investment in Series B - Ultragenyx Pharmaceutical
HealthCap
HealthCap investment in Series A - Ultragenyx Pharmaceutical
F-Prime Capital
F-Prime Capital investment in Series A - Ultragenyx Pharmaceutical
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-10-23 | Solid Biosciences | Ultragenyx Pharmaceutical investment in Post-IPO Equity - Solid Biosciences | 40 M USD |
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2023-07-12 | Ultragenyx Pharmaceutical appoints CFO |
| 2023-03-14 | Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President |
| 2022-11-10 | Ultragenyx Announces Departure of Chief Financial Officer |
Official Site Inspections
http://www.ultragenyx.com Semrush global rank: 1.03 M Semrush visits lastest month: 26.72 K
- Host name: 104.18.26.199
- IP address: 104.18.26.199
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ultragenyx Pharmaceutical"
Ultragenyx—Treatment of Rare and Ultrarare Genetic …
“Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and …See details»
Corporate Responsibility—Ultragenyx
*A subset of the employee engagement survey—focused on employee pride in our company, whether an employee would recommend Ultragenyx as a good place to work, whether an employee experiences a feeling of personal …See details»
Policy, Government and Public Affairs - Ultragenyx
What we do Ultragenyx’s Policy, Government and Public Affairs team exists to foster a thriving environment for rare and ultrarare disease drug development and commercialization to …See details»
Corporate Presentation - Ultragenyx Pharmaceutical Inc.
Corporate Presentation - Ultragenyx Pharmaceutical Inc.See details»
Investors & Media—Ultragenyx Pharmaceutical Inc.
Oct 29, 2024 Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has …See details»
Ultragenyx Pharmaceutical - Crunchbase Company …
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in …See details»
Ultragenyx - LinkedIn
Ultragenyx | 84,561 followers on LinkedIn. Going Beyond Every Day | Leading with purpose. Every day. “Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that ...See details»
Ultragenyx | Rare Disease Medical Research | Now …
Ultragenyx is dedicated to improving life for people with rare and ultra-rare diseases, and their family and caregivers, through the creation and discovery of much-needed therapies. Our advanced clinical development programs cover …See details»
Ultragenyx Mission, Benefits, and Work Culture
At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. ... Ultimately, we want to be an organization where we would be proud for our …See details»
Ultragenyx’s Corporate Sustainability Journey
Nov 22, 2022 Ultragenyx was founded in 2010 to develop medicines for rare and ultrarare diseases and a core ethos to treat as many rare disease patients as possible. As we developed our inaugural ESG report for 2021, we reflected on …See details»
Ultragenyx, a Rare Disease Powerhouse in Less Than 15 Years
Oct 30, 2024 Focused on rare and ultra-rare genetic diseases, Ultragenyx identifies itself as the industry’s most productive company working in the field of high un-met need diseases. With no …See details»
Patient Advocacy Groups - Ultragenyx
Ultragenyx works side by side with organizations that provide educational resources and support for those affected by rare disorders. The organizations listed on this page have information …See details»
GeneTx and Ultragenyx Receive Clearance from Health Canada to …
May 19, 2021 GeneTx was launched by FAST, a patient advocacy organization and the largest non-governmental funder of Angelman syndrome research. GeneTx licensed the rights to …See details»
Ultragenyx Patient Advocacy - Rare and UltraRare Diseases
Ultragenyx Advocacy. Our Advocacy Team; Follow Us. Follow us on Facebook Follow us on LinkedIn. In the company of parents, protectors, and proud partners in care. Where are you in …See details»
Our RARE Formula Aligns Strategy and Culture for ... - Ultragenyx
Nov 3, 2021 When I first started working with Ultragenyx in 2015, I collaborated with the Executive Team to create the company’s 2020 vision and strategy. We shared it with the then …See details»
Ultragenyx Announces Partnership with GeneTx to Advance …
Aug 14, 2019 Ultragenyx receives an exclusive option to acquire GeneTx. NOVATO, Calif. and DOWNERS GROVE, Ill., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical …See details»
Ultragenyx to spin out new company around Alzheimer’s gene …
Oct 18, 2023 Ultragenyx will spin out a new company to take advantage of research it claims could lead to a new way of treating Alzheimer’s disease. Researchers working for the …See details»
Canadian English - Ultragenyx
Visit Ultragenyx.com Leading the future of rare disease medicine for patients like Mason. We use our experience, insight, and commitment to move the rare disease community forward. Our …See details»
Ultragenyx: A Promising Bet On Rare Genetic Disorder Therapies
May 29, 2023 Ultragenyx's pipeline boasts a diverse array of gene therapy candidates, including UX111, DTX401, DTX301, and UX701, offering transformative potential in the treatment of …See details»